Immune agents for the treatment of Devic’s neuromyelitis optica
- 31 October 2007
- journal article
- Published by Springer Nature in Neurological Sciences
- Vol. 28 (5) , 238-240
- https://doi.org/10.1007/s10072-007-0828-7
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Variable responses to rituximab treatment in neuromyelitis optica (Devic’s disease)Neurological Sciences, 2007
- Rituxan warning.2007
- NMO-IgG in the diagnosis of neuromyelitis opticaNeurology, 2007
- Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission after treatment with cytostatics and rituximab: case report and review of the literatureClinical Neuropathology, 2007
- Sustained improvement of a girl affected with Devic's disease over 2 years of mycophenolate mofetil treatmentRheumatology, 2006
- Devic?s neuromyelitis optica: clinical features and prognostic factorsNeurological Sciences, 2004
- Devic's Neuromyelitis Optica Treated with Intravenous Gamma Globulin (IVIG)Canadian Journal of Neurological Sciences, 2004
- Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapyBrain, 2002
- A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis opticaBrain, 2002
- Devic's neuromyelitis optica: A clinicopathological study of 8 patientsAnnals of Neurology, 1993